Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non–muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study
This is the first and largest report on factors affecting FGFR test results. To ensure valid FGFR test results, adequate tumor sample amount, RNA quality, short archival sample age, and primary tumor samples are important factors.
Authors
- Spyros Triantos
- Nobuaki Matsubara (ORCID: https://orcid.org/0000-0002-9203-4245)
- Jason Hwang (ORCID: https://orcid.org/0000-0001-5191-0950)
- Jenna Carcione (ORCID: https://orcid.org/0000-0002-5047-9422)
- Shibu Thomas
- Séverine Banek
- Begoña P. Valderrama (ORCID: https://orcid.org/0000-0003-0175-1263)
- Arlene O. Siefker‐Radtke (ORCID: https://orcid.org/0000-0002-6328-9599)
- Kris Deprince
- Sanket Patel
- Yohann Loriot
Institutions
- Goethe University Frankfurt (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Janssen (Belgium) (BE)
- Inserm (FR)
- Institut Gustave Roussy (FR)
- University Hospital Frankfurt (DE)
- National Cancer Center Hospital East (JP)
- Janssen (United States) (US)
- Hospital Universitario Virgen del Rocío (ES)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.euo.2025.07.009
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01